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Introduction
Allogeneic haematopoietic stem cell transplantation (HSCT) is an established therapy for many patients with acute leukaemia [1] . Severe acute graftversus-host disease (GVHD) is a life-threatening complication after HSCT [2] [3] [4] . Corticosteroids are the first-line therapy for moderate-to-severe acute GVHD, with a response rate of 30-50%, but nonresponders have a low survival rate [1, 2, [4] [5] [6] [7] . Because of the poor response in steroid-refractory acute GVHD, a wide range of immunosuppressive therapies have been tried including antithymocyte globulin (ATG), extracorporeal photopheresis, mycophenolate mofetil, inolimomab, daclizumab, sirolimus, infliximab, alemtuzumab, methotrexate, basiliximab, monoclonal anti-CD3 antibodies, denileukin diftitoxin, tacrolimus, pulses of cyclophosphamide, pentostatin, mesenchymal stromal cells (MSCs) and etanercept [7, 8] . In more recent years, the outcome after HSCT has generally improved due to better diagnosis, better prophylaxis, better treatment of infections and improved patient care [9] [10] [11] [12] .
Regarding severe acute GVHD, several novel therapies have been introduced, including MSCs [13] [14] [15] . Placenta-derived decidual stromal cells appear to be promising for treatment of steroid-refractory acute GVHD, with one-year survival rates similar to that in patients without severe acute GVHD [16] , Ringd en et al., unpublished data). Use of the JAK 1/2 inhibitor ruxolitinib has shown encouraging results for both acute and chronic GVHD [17, 18] . Increased knowledge of GVHD biology and transferring experimental data into the clinic include novel strategies such as na€ ıve T-cell depletion, focused cytokine and chemokine inhibition, and the blockade of costimulation. These therapies are likely to be investigated in patients in the near future [19] . Use of the CCR5 antagonist maraviroc appears promising in visceral GVHD [20] . Brentuximab against CD30, which has increased expression on CD8 + T cells during acute GVHD, was investigated for steroid-refractory acute GVHD [21] . Regulatory T cells may also be used for treatment of acute GVHD [22] . Histone deacetylase inhibitors showed a high response rate (85%) when added to steroids as first-line treatment of acute GVHD [23] . Aurora kinase A inhibitors have shown promise in mouse models for GVHD, and they may be developed and used in the clinic [24] . Vedolizumab, an integrin antibody that is used to treat Crohn's disease, seems promising for treatment of severe acute GVHD [25, 26] . With all these novel therapies, it is to be expected that a higher proportion of patients will survive severe acute GVHD. The aim of this study was to analyse the outcome in patients with severe acute GVHD who were still alive six months after HSCT.
Methods
This was based on registry data covering 23 563 patients with acute leukaemia who underwent HSCT during 2000-2014. Of 36.298 patients, 12.735 were excluded, because follow-up was less than 6 months (n = 3.028), relapse before 6 months and death before 6 months (n = 6.745). The patients were reported to the Acute Leukaemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Informed consent was obtained from all the patients. The EBMT is a group of 605 HSCT centres that report all consecutive transplants. Patients were included from 338 centres. All patients were alive without relapse six months after transplantation. Patients who received cord blood transplants and haploidentical grafts were excluded. A landmark analysis was performed at six months after allogeneic transplantation. Only first transplants were included. The study group included 1738 patients with acute GVHD of grades III-IV within 100 days after HSCT. They were compared to patients with acute GVHD of grades 0-I (control group 1, n = 17 292) and grade II (control group 2, n = 4533).
There were several differences between the three groups with acute GVHD of grades 0-I, II and III-IV, respectively (Table 1) . Patients with severe acute GVHD were generally younger and were more often males with acute lymphoblastic leukaemia (ALL), secondary leukaemia and female donors for male recipients. They more often had advanced disease, had more PBSC grafts, had more unrelated donors, had more poor-risk cytogenetics, more often received in vivo T-cell depletion and more often developed chronic GVHD before six months.
Conditioning and immunosuppression
Myeloablative conditioning (MAC) was given to 72% of the severe acute GVHD patients, as opposed to 65% in control group 1 and 74% in control group 2. The most common MAC regimens in control group 1, control group 2 and the severe GVHD group were based on total body irradiation (TBI) (49%/56%/ 58%) and a combination of busulfan (Bu) and cyclophosphamide (Cy) (given to 25%/21%/23%). Other MAC regimens included Bu and fludarabine (Flu) (8%/7%/5%), treosulfan and Flu (4%/2%/ 2%) and Flu combined with melphalan (2%/1%/ 2%). The three most common RIC regimens used were Bu/Flu (38%/33%/27%), Flu/Mel (29%/ 31%/32%) and sequential chemotherapy followed by TBI (6%/8%/8%).
For prevention of acute GVHD, the most commonly used immunosuppressive protocols included [27] . Less patients in the study group than in the control groups received in vivo or in vitro T-cell depletion ( Table 1) .
Definition of outcomes
Acute and chronic GVHD were scored according to the Seattle criteria [28] [29] [30] . Chronic GVHD was described according to the time of occurrence (before or after 6 months from transplantation). The primary outcomes were as follows: nonrelapse mortality (NRM), defined as all causes of death that were not due to leukaemia; relapse incidence, defined on the basis of morphological evidence of leukaemia in the bone marrow or other extramedullary organs (to evaluate the probability of relapse, patients who died from direct toxicity of the procedure or from causes not related to leukaemia were censored); leukaemia-free survival (LFS), defined as the time from transplantation to the first event (relapse or death in complete remission); and overall survival (OS).
Cytogenetic abnormalities were classified as good, including t(8;21), t(15;17), and inv (16) or del [31] , alone or combined with others, poor (including 11q23 abnormalities or chromosomes 5 and 7, and complex karyotype (≥3 abnormalities), and intermediate (compromising all the other cytogenetic aberrations, including trisomies) [31] . Secondary AML (acute myeloid leukaemia) was kept in a separate group.
Statistical analysis
The aim of the study was to compare the outcome in patients 6 months after transplantation according to the presence and the grade of previous acute GVHD. The landmark analysis started at 6 months after transplantation. Cumulative incidence functions (CIFs) were used to estimate RI and NRM in a competing-risks setting, because death and relapse compete with each other. Probabilities of LFS and OS were calculated using the KaplanMeier estimates. The incidence of chronic GVHD after 6 months was estimated in patients without previous chronic GVHD, competing events being relapse or death after 6 months.
Patient-, disease-and transplant-related variables were compared between the three groups using the chi-square statistic for categorical variables and the Kruskal-Wallis test for continuous variables. Variables considered were the patient's age at transplantation, diagnosis (AML or ALL), sex of donor/recipient, secondary AL, status at the time of transplantation (CR1, CR2 + or active disease), source of stem cells (peripheral blood (PB) or bone marrow (BM)), type of donor (matched sibling or unrelated), cytogenetics, conditioning intensity, use of ex vivo or in vivo T-cell depletion, interval from diagnosis to transplant, CMV seropositivity of patient/donor, previous donor lymphocyte infusion (DLI) and chronic GVHD within 6 months of transplantation. All factors that differed significantly between the three groups (with P-values of <0.05), and factors associated with the outcome by univariate analysis were included in the final models. Univariate analyses were performed using 
Results

Engraftment
At six months, neutrophil engraftment (>0.5 9 10 9 /L) was achieved in all study patients. This was similar to 99% in the controls, where only four patients failed for neutrophil engraftment. A platelet count of >20 9 10 9 /L was seen in all the patients.
Acute GVHD
In the entire population, the cumulative incidence of acute GVHD grade II-IV was 28% (95% CI 28-28.9). The cumulative incidence of grades III-IV was 10.5% ( 
Chronic GVHD
Chronic GVHD before six months occurred in 39% of the patients with severe acute GVHD, as opposed to 21.5% in control group 1 and 33.5% in control group 2 (P < 10 -5 ). The probability of extensive chronic GVHD before six months was 26.9%, 10% and 17.5%, respectively (P < 10
À5
). Six months after transplantation, the numbers of patients who were alive without relapse and with no previous chronic GVHD in the three groups were 1059 in the study group, 13 568 in control group 1 and 3016 in the control group 2. In the study group, the cumulative incidence of chronic GVHD at 5 years was 47.8% (95% confidence interval (CI) 44.6-51), as opposed to 30.4% (29.6-31.2) in control group 1 and 41.7% (39.8-43.6) in control group 2 (P < 10 À5 ) (Fig. 1a) . The corresponding figures for extensive chronic GVHD were 27.2% (24.5-30), 12.7% (12.1-13.2) and 20.2% (18.8-21.7), respectively (P < 10 -5 ) (Fig. 1b) .
Nonrelapse mortality ). Factors significant for NRM in multivariate analysis were severe acute GVHD versus controls, high age, ALL rather than AML, secondary acute leukaemia, active disease (versus CR1), UD (versus MSD), PB (versus BM), RIC or NMA versus MAC, no in vivo T-cell depletion, ex vivo T-cell depletion, DLI given before six months and chronic GVHD before six months (Table 2) .
Relapse
The probability of relapse at 5 years in the study patients was 18.4% (16.5-20.5), as compared to 27.4% (26.6-28.1) in control group 1 and 22.6% (21.2-23.9) in control group 2 (P < 10 -5 ) (Fig. 2b ). Factors associated with an increased risk of relapse in multivariate analysis included patients with severe acute GVHD versus controls, ALL, advanced disease, MSD grafts (rather than UD grafts), RIC and NMA rather than MAC, in vivo Tcell depletion, the year of transplantation, time from diagnosis to transplantation and chronic GVHD within six months of transplantation (Table 2) .
LFS and survival
LFS at 5 years in patients with severe acute GVHD was 49.2% (46.5-51.9), as opposed to Outcome of severe acute GVHD in acute leukaemia / O. Ringd en et al. 60 .9% (60-61.7) in control group 1 and 58.9% (57.3-60.5) in control group 2 (P < 10 À5 ) (Fig. 2c) . In the multivariate analysis, a decreased LFS was associated with severe acute GVHD compared to the controls, high age, ALL (rather than AML), secondary acute leukaemia, more advanced disease stage, RIC and NMA rather than MAC, in vivo T-cell depletion, ex vivo T-cell depletion, DLI before six months and chronic GVHD before six months (Table 3) .
Overall survival at 5 years in patients with severe acute GVHD was 51.4% (48.6-54.1), as opposed to 66.4% (65.6-67.3) in control group 1 and 62.3% (60.7-64) in control group 2 (P < 10 À5 ) (Fig. 2d) . In the multivariate analysis, risk factors for a reduced overall survival were the same as those associated with LFS (Table 3 ). The only difference was that in vivo T-cell depletion was not associated with a decreased risk of survival. Year of transplant was not associated with survival (P = 0.73) or LFS (P = 0.098).
Causes of death in patients with severe acute GVHD, in control group 1 and in control group 2 were leukaemic relapse (36%/70%/54%), GVHD (35%/ 13%/22%), infection (19%/10%/14%), secondary malignancy (1.2%/2.7%/3.1%), interstitial pneumonitis (1.2%/1.2%/1.6%), haemorrhaging (1.2%/ 0.3%/0.3%), cardiac toxicity (0.6%/0.3%/0.4%), allograft rejection (0%/0.2%/0.1%), sinusoidal obstructive syndrome (0.6%/0.2%/0.1%) and other transplant-related reasons (5.3%/3.1%/5.3%).
Discussion
Half of the patients with severe acute GVHD developed extensive chronic GVHD, which is a devastating problem, and its incidence was significantly higher than in the controls (P < 10
À5
). There is a close correlation between acute GVHD and chronic GVHD [32] [33] [34] . The outcome in patients with extensive and severe chronic GVHD is poor [29] . Furthermore, there is no effective therapy for severe chronic GVHD, which is a major burden. It is therefore important not only to control acute GVHD, but also to study whether novel therapies will be able to prevent the development of chronic GVHD. Such therapeutics -including ruxolitinib and decidual stromal cells -show some promise in this respect [18] (Solders et al., unpublished data).
It is expected that NRM is higher in patients with severe acute GVHD than in all other patients [2, [4] [5] [6] [7] [8] . Several complications such as infections due to GVHD and the heavy immunosuppressive therapy can be expected to be high in these patients. At 5 years, there was an increase in NRM of 20% for severe acute GVHD patients compared to those with mild or no acute GVHD. Several well-known risk factors for high NRM were identified (Table 2 ) [1, [10] [11] [12] . A significantly increased NRM was seen in patients who received T-cell depleted grafts, which is in line with previous data [35] . In contrast, in vivo T-cell depletion was associated with improved NRM, which agrees with several other reports [36, 37] .
Relapse probability was significantly lower in those patients with severe acute GVHD than in the (Table 2 ). This may have been partly due to the fact that T cells causing acute GVHD may have a direct effect on leukaemic cells. It was previously shown in a study by the CIBMTR that ALL patients with acute GVHD had a reduced probability of relapse [38] . However, a more important consideration might be that patients with severe acute GVHD also appear to have a high probability of developing chronic GVHD, almost 70% in the present study, which was significantly higher than that in the controls (P < 10
). Several studies have shown that the graft-versus-leukaemia effect is stronger for chronic GVHD than for acute GVHD [38] [39] [40] . Several additional factors were associated with an increased risk of leukaemic relapse -among others, more advanced disease, RIC rather than MAC, T-cell depletion of the grafts and absence of chronic GVHD, which is in Outcome of severe acute GVHD in acute leukaemia / O. Ringd en et al.
agreement with the results of several previous studies (Table 3) [38, 39] . DLI had no significant effect on the probability of relapse, while it increased NRM (Table 2 ). This contrasts with the effect of DLI in patients with chronic myeloid leukaemia, where the probability of relapse is reduced and LFS is increased [41, 42] .
LFS was only around 10% worse for patients who survived severe acute GVHD than for the controls. This may be due to the fact that the high NRM is compensated for by a stronger graft-versusleukaemia effect with lower relapse probability. Still, there was a significant difference in LFS and also OS in patients with severe acute GVHD relative to the controls (Table 3 ). This analysis showed that patients who underwent conditioning with RIC or NMA had a worse LFS and OS than those treated with MAC (Table 3 ). This may seem contradictory compared to many other studies, which have shown that patients with RIC have a lower NRM, increased risk of relapse and similar LFS and OS compared to those treated with MAC [43] [44] [45] . In the present analysis, there was no reduction in NRM with RIC rather than MAC. This is most probably due to the fact that this was a landmark analysis and patients who died early due to toxicity and various other causes linked to conditioning were excluded.
Ex vivo T-cell depletion led to reduced LFS and survival. However, in vivo T-cell depletion reduced LFS but not survival. The reason for this was that in vivo T-cell depletion may also increase the NRM, nonrelapse mortality; aGVHD, acute graft-versus-host disease; ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; sec, secondary; CR, complete remission; UD, unrelated donor; MSD, matched sibling donor; PB, peripheral blood stem cell graft; BM, bone marrow graft, RIC, reduced-intensity conditioning; MAC; myeloablative conditioning; NMA, nonmyeloablative; TCD, T-cell depletion; CMV, cytomegalovirus; DLI, donor lymphocyte infusion; cGVHD, chronic graft-versus-host disease.
risk of relapse [35, 46] . In the long run, this will also reduce the probability of survival, as was seen for in vivo T-cell depletion. Chronic GVHD before six months was a poor prognostic factor and led to reduced LFS and survival. This was seen despite the reduced risk of relapse because early chronic GVHD also led to increased NRM (Tables 2 and 3 ).
Leukaemic relapse was the most common cause of death in all three GVHD groups. The risk was lowest in those with severe acute GVHD. Death from GVHD, infection and haemorrhaging tended to be more common in those with severe acute GVHD than in the controls. There were no patients with graft failure/rejection in those with severe acute GVHD, as compared to 11 (0.2%) and 2 (0.1%) in control groups 1 and 2, respectively. This may have been due to the fact that a stronger alloreactivity wipes out recipient immunocompetent T cells, and therefore, rejection is less likely to occur. Acute GVHD is also associated with full donor chimerism [47] . Secondary malignancies were only seen in eight patients who survived severe acute GVHD (1.2%), which appeared to be lower than in around 3% of the controls.
The findings in this study should be interpreted with caution, because this was a retrospective registry study with its obvious shortcomings. NRM and relapse are important, but crude end-points. More optimal would be to examine NRM, nonrelapse mortality; aGVHD, acute graft-versus-host disease; ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; sec, secondary; CR, complete remission; UD, unrelated donor; MSD, matched sibling donor; PB, peripheral blood stem cell graft; BM, bone marrow graft, RIC, reduced-intensity conditioning; MAC; myeloablative conditioning; NMA, nonmyeloablative; TCD, T-cell depletion; CMV, cytomegalovirus; DLI, donor lymphocyte infusion; cGVHD, chronic graft-versus-host disease.
'dependency of corticosteroids' or quality of life measurements. Unfortunately, such data are not available in the EBMT registry. Another limitation is that disease-specific information such as proportion of Ph+ ALL and FLT3-status in AML patients is lacking. Therefore, the findings about relapse risk should be drawn cautiously. However, a study of this kind would not have been possible without including patients from many centres. This study will serve as a basis for what can be expected in patients who survive severe acute GVHD. It can also be used as a reference study for patients with severe acute GVHD who are treated with novel therapies such as mesenchymal stromal cells, placenta-derived decidual stromal cells, ruxolitinib, vedolizumab (anti-integrin antibodies) and others to come [13-16, 18-20, 22-24, 26 ].
In conclusion, half of the patients who survived severe acute GVHD six months after HSCT developed extensive chronic GVHD. Within five years, one-third of the patients can be expected to die from NRM. Relapse probability is lower than in control patients with no GVHD or milder forms, and LFS and OS are around 10-15% lower than for the controls.
